Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
6 evidence topics · 9 sources
Phase 3 dose: single 100 µg DT120 ODT
Symptom-triggered open-label redosing in the 40-week extension
Dose selection from the phase 2b dose-finding trial
“In this phase 2b, multicenter, double-blind, placebo-controlled trial, participants with GAD were randomized equally to receive a single (freebase equivalent) treatment dose with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 or placebo without stratification (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 100-µg dose of MM120 was determined to be optimal, demonstrating a statistically significant change in GAD that exceeded the changes seen with lower MM120 doses or with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 200-µg dose of MM120 was associated with more frequent AEs without improvements in efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings support the selection of 100-µg dose of MM120 for pivotal trials to assess its efficacy, durability, and safety in the treatment of GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-response in healthy participants above 100 µg
“Therefore, LSD doses higher than 100 µg produced no further increases in good drug effects but more ego dissolution and anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results may assist with dose finding for future LSD research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Characterization of the 100 µg dose in an independent drug review
“The phase 2b dose-finding study provides a credible signal of rapid and durable anxiolytic activity after one 100 microgram administration without protocol-mandated psychotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, DT120 should not be described as microdosing or modified release: 100 micrograms is a perceptible psychedelic dose, whereas controlled microdosing studies have generally used 5-20 micrograms, and the pivotal product is described publicly as a fast-dissolving orally disintegrating tablet.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote